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AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE

A Randomized Trial of Obeticholic Acid
Monotherapy in Patients With Primary
Biliary Cholangitis
Kris V. Kowdley,1 Velimir Luketic,2 Roger Chapman,3 Gideon M. Hirschﬁeld,4 Raoul Poupon,5 Christoph Schramm,6
Catherine Vincent,7 Christian Rust,8 Albert Pares,9 Andrew Mason,10 Hanns-Ulrich Marschall,11 David Shapiro,12
Luciano Adorini,12 Cathi Sciacca,12 Tessa Beecher-Jones,12 Olaf B€ohm,13 Richard Pencek,12 and David Jones,14
for the Obeticholic Acid PBC Monotherapy Study Group
Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized,
double-blind, placebo-controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years.
The goals of the study were to assess the beneﬁt of OCA in the absence of ursodeoxycholic acid, which is relevant for patients who
are intolerant of ursodeoxycholic acid and at higher risk of disease progression. Patients were randomized and dosed with placebo
(n 5 23), OCA 10 mg (n 5 20), or OCA 50 mg (n 5 16) given as monotherapy once daily for 3 months (1 randomized patient
withdrew prior to dosing). The primary endpoint was the percent change in alkaline phosphatase from baseline to the end of the
double-blind phase of the study. Secondary and exploratory endpoints included change from baseline to month 3/early termination
in markers of cholestasis, hepatocellular injury, and farnesoid X receptor activation. Efﬁcacy and safety continue to be monitored
through an ongoing 6-year open-label extension (N 5 28). Alkaline phosphatase was reduced in both OCA groups (median%
[Q1, Q3], OCA 10 mg 253.9% [262.5, 229.3], OCA 50 mg 237.2% [254.8, 224.6]) compared to placebo (20.8% [26.4,
8.7]; P < 0.0001) at the end of the study, with similar reductions observed through 6 years of open-label extension treatment. OCA
improved many secondary and exploratory endpoints (including c-glutamyl transpeptidase, alanine aminotransferase, conjugated
bilirubin, and immunoglobulin M). Pruritus was the most common adverse event; 15% (OCA 10 mg) and 38% (OCA 50 mg) discontinued due to pruritus. Conclusion: OCA monotherapy signiﬁcantly improved alkaline phosphatase and other biochemical
markers predictive of improved long-term clinical outcomes. Pruritus increased dose-dependently with OCA treatment. Biochemical improvements were observed through 6 years of open-label extension treatment. (HEPATOLOGY 2018;67:1890-1902).
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P

rimary biliary cholangitis (PBC), formerly
known as “primary biliary cirrhosis,” is a chronic
liver disease predominantly affecting women
(10:1) and commonly diagnosed between 40 and 60
years of age.(1,2) While the pathogenesis of PBC is multifactorial and incompletely understood, the pathology,
symptoms, and course of the disease are typically associated with cholestasis and increased liver concentrations
of bile acids.(3,4) Untreated, PBC may progress to cirrhosis, hepatic decompensation, and liver transplantation

and/or death.(5,6) Elevated alkaline phosphatase (ALP)
levels and other biochemical parameters associated with
liver function and cholestasis have been correlated with
clinical outcomes in PBC.(7) Until recently, ursodeoxycholic acid (UDCA) was the only approved therapy for
PBC and has been recommended as the standard of
care.(3,4) However, elevated ALP levels persist in up to
40% of UDCA-treated patients, and their mortality risk
remains higher than that for the general population,
demonstrating the need for additional therapies.(6,8)
While the majority of patients take UDCA, a minority
are unable to tolerate UDCA, primarily due to adverse

Abbreviations: AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C4, 7a-hydroxycholest-4-en-3-one; EOS, end of study; ET, early termination; FGF-19, ﬁbrosis growth factor-19; FXR, farnesoid X receptor; GGT, c-glutamyl
transpeptidase; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; IgM, immunoglobulin M; OCA, obeticholic
acid; OLE, open-label extension; PBC, primary biliary cholangitis; TNF-a, tumor necrosis factor-a; UDCA, ursodeoxycholic acid; ULN, upper limit of
normal.
Received April 21, 2017; accepted September 27, 2017.
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.29569/suppinfo.
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events (AEs) such as gastrointestinal symptoms.(9)
Patients who do not receive UDCA treatment have
diminished liver transplant-free survival.(7) In addition to
the clear unmet need in patients who are intolerant to
standard of care, when evaluating new therapies it is critical to understand each new treatment’s unique clinical
proﬁle to fully gauge its clinical utility and assess whether
a new therapy may be adequate alone or serve as a
second-line therapy. As such, obeticholic acid (OCA)
was evaluated as a monotherapy in the absence of
UDCA in patients with PBC.
OCA is a modiﬁed bile acid with a similar structure
to chenodeoxycholic acid, the endogenous farnesoid X
receptor (FXR) ligand. The addition of an ethyl group
on the six-carbon confers OCA with 100-fold greater
potency for FXR relative to chenodeoxycholic acid.(10)
FXR activation results in repression of cholesterol 7ahydroxylase, the enzyme catalyzing the rate-limiting
step of bile acid synthesis,(11) and induces production of
an ileum-derived enterokine, ﬁbroblast growth factor-19
(FGF-19), which functions as a negative regulator of
bile acid synthesis.(12) Additionally, FXR activation regulates the expression of key bile acid transporters; it upregulates organic solute transporters and the bile salt
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export pump, which increase bile acid ﬂux from the
hepatocytes into bile.(13) The sum of these effects are
reduced bile acid synthesis and improved choleresis.(1113)
In previous studies, FXR activation through OCA
treatment elicited anticholestatic, antiﬁbrotic, and antiinﬂammatory effects.(10,14,15) In a phase 3 study of
OCA in patients with PBC with an inadequate
response to UDCA or who could not tolerate UDCA,
only 7% of patients received OCA as a monotherapy.(15)
Given the unmet need in this patient population, further
evaluation of OCA as monotherapy is warranted.
The objectives of this phase 2 study were to investigate the safety, tolerability, and efﬁcacy of daily OCA
10 mg and OCA 50 mg administered as a monotherapy compared to placebo. Furthermore, this study evaluated the efﬁcacy, safety, and durability of treatment
with OCA in an ongoing open-label extension (OLE)
with up to 6 years of treatment.

Participants and Methods
The study protocol was approved by regulatory
authorities and institutional review boards or
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institutional ethics committees at each site. The study
was conducted according to good clinical practice
guidelines and the Declaration of Helsinki and is
reported in accordance with Consolidated Standards of
Reporting Trials guidelines. The double-blind phase
was conducted between November 2007 and September 2010 at 18 centers in six countries. Enrollment was
stopped once results were available for the parallel
phase 2 study of OCA in combination with UDCA.(8)
The OLE was not part of the original study design but
was initiated in November 2008; as a result, some
patients had varying durations between the end of the
double-blind phase and the start of the OLE (mean
[SD], 58 [101] days). The OLE remains ongoing to
further monitor safety and efﬁcacy. Additional study
information is available in the Supporting Information.

STUDY DESIGN
This was an international, double-blind, placebocontrolled study of OCA monotherapy in patients with
PBC. Doses investigated in this study were doseﬁnding and different from those later investigated in
phase 3 studies of OCA. At the time of this study, only
phase 1 data of OCA were available, testing doses of
25-500 mg in healthy volunteers. No substantial AEs
were observed at 50 mg, which was therefore considered an appropriate potential dose. Patients meeting
enrollment criteria were randomized 1:1:1 to OCA 10
mg, OCA 50 mg, or placebo, administered once daily
for 3 months. The computerized randomization schedule used a block size of 3 at each center. Patients were
assessed at week 2, month 1, month 2, and month 3
(end of the double-blind phase). All patients had a
follow-up visit 2 weeks after study medication discontinuation. Patients who discontinued the study early
(and thereby stopped usage of OCA) had an early termination (ET) visit. The primary endpoint of the study
was the median percent change in ALP from baseline
to the end of study (EOS). After completion of the
double-blind phase, patients could enroll in an OLE.

HEPATOLOGY, May 2018

(ULN; normal ALP, 120 U/L) at screening. Key
exclusion criteria were elevated plasma aspartate
aminotransferase (AST) or alanine aminotransferase
(ALT) levels >5 times the ULN; conjugated bilirubin
>2 times the ULN; serum creatinine >1.5 mg/dL
(133 lmol/L); the use of colchicine, methotrexate, azathioprine, or systemic corticosteroids during the 3
months prior to screening; history or presence of hepatic
decompensation; and concomitant liver diseases.

EFFICACY ANALYSES
The primary endpoint was the percent change in
ALP from baseline to EOS (month 3 or ET in the
case of premature discontinuations or the last observed
ALP level for patients who did not complete the
study). The last observation carried forward method
was used for missing data for the primary endpoint
only. For secondary and exploratory endpoints, month
3 values included ET data in the cases of discontinuations when ET data were available. Secondary
endpoints included change in ALP, c-glutamyl transpeptidase (GGT), ALT, AST, conjugated bilirubin,
and achieving previously developed response criteria
in PBC.(6) Exploratory endpoints included change
from baseline in high sensitivity C-reactive protein
(hsCRP), tumor necrosis factor-a (TNF-a), transforming growth factor-b, immunoglobulin M (IgM),
glutathione, osteopontin, albumin, nonesteriﬁed fatty
acids, FGF-19, enhanced liver ﬁbrosis score, PBC-40
questionnaire, Short Form 36 survey, and achieving
different thresholds of ALP decrease. Additional post
hoc analyses included change in 7a-hydroxycholest-4en-3-one (C4), a bile acid precursor used to assess bile
acid synthesis, and estimated future survival based on
the UK-PBC and Global PBC prognostic models.(16,17) Safety assessments included AEs as deﬁned
by the Medical Dictionary for Regulatory Activities,
physical examinations, vital signs, pruritus visual analogue scale score, Pruritus 5D questionnaire, and electrocardiograms. Additional methods can be found in
the Supporting Information.

ELIGIBILITY CRITERIA
Patients were 18-75 years old and either UDCAnaive or not taking UDCA for 3 months prior to
screening (Supporting Fig. S1). Key inclusion criteria
included PBC diagnosis by the American Association
for the Study of Liver Diseases/European Association
for the Study of the Liver guidelines(3,4) and serum
ALP 1.5-10 times the upper limit of normal range
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OPEN-LABEL EXTENSION
Patients completing the double-blind phase were
eligible for the OLE. Placebo-treated patients or
patients who had been off therapy for 1 month after
the double-blind phase were started on OCA 10 mg.
OCA-treated patients completing the double-blind
phase resumed their double-blind dose during the

HEPATOLOGY, Vol. 67, No. 5, 2018

OLE phase. During the OLE, investigators could
titrate doses up to 75 mg based on therapeutic
response. The OCA dose could be reduced during the
OLE based on the physician’s discretion. UDCA
could be initiated during the OLE phase at the investigator’s discretion. The primary objectives of the OLE
were to assess the long-term safety and efﬁcacy of
OCA.

SAMPLE SIZE
The planned sample size was 40 patients/treatment group. Absent an a priori estimate of treatment
effect and assuming a type I error of 5%, a cohort size
of 40 patients/treatment arm was calculated to provide
80% power to detect an effect size of 0.6466 or 70%
power to detect an effect size of 0.5770. The rarity of
PBC, coupled with the inclusion criterion that patients
not be taking UDCA, resulted in a ﬁnal sample size of
20 patients/group, resulting in 49% power to detect
an effect size of 0.6466 for the difference in the primary efﬁcacy endpoint between treatment arms and
placebo using a Wilcoxon-Mann-Whitney rank-sum
test with a 0.05 two-sided signiﬁcance level.

STATISTICAL ANALYSES
The primary efﬁcacy endpoint was analyzed using a
two-sided Wilcoxon-Mann-Whitney test to perform
pairwise comparisons of changes in each OCA group
with the placebo group. A hierarchical testing strategy(18) accounted for multiple comparisons: OCA 10
mg versus placebo was tested ﬁrst at a 5 0.05 and
once signiﬁcance was shown; then OCA 50 mg versus
placebo was tested at a 5 0.05.
Secondary, exploratory, and safety endpoints were
summarized by treatment group using descriptive statistics. All data refer to median (Q1, Q3) values unless
otherwise speciﬁed. For continuous endpoints, exploratory endpoints, safety endpoints (pruritus visual analogue scale score/5D questionnaire), and post hoc
analysis of C4, pairwise comparisons of placebo versus
each OCA group used the two-sided WilcoxonMann-Whitney test. For categorical and exploratory
variables, each OCA group was compared to placebo
using a Fisher’s exact test. All tests were evaluated at
a 5 0.05 with no adjustments for multiplicity.
Post hoc comparisons between each OCA group and
placebo for the UK-PBC and Global PBC prognostic
models were obtained using a rank analysis of covariance model with baseline value as a covariate.

KOWDLEY ET AL.

Analyses were performed using SAS version 9.1.3 or
newer. All graphs and ﬁgures were produced in
GraphPad Prism version 6.0.

Results
STUDY PATIENTS
Sixty patients were randomized into the study; 1
withdrew prior to dosing, yielding a study population
of 59 patients. Patient disposition, demographics, and
baseline characteristics are summarized in Table 1 and
in Supporting Fig. S1 and Table S1. Demographics
and baseline clinical characteristics were generally similar between treatment groups. The patients were 85%
female, 95% white, and 54 (48, 61) years of age. ALP
and GGT were elevated at baseline in all groups
(Table 1). While the reason for not receiving UDCA
was not captured in this study, the median PBC disease duration ranged 1.0-2.1 years (Table 1), suggesting that many patients may have been UDCA-naive.
While baseline liver enzymes were elevated in most
patients, the short disease duration and the moderate
estimated 10-year survival suggest that most patients
were early in the PBC stage. Forty-eight patients
(81%) completed the 3-month double-blind phase of
the study (placebo, 23 patients [100%]; OCA 10 mg,
16 patients [80%]; OCA 50 mg, 9 patients [56%]).
Reasons for study discontinuation were pruritus (OCA
10 mg, 3 patients [15%]; OCA 50 mg, 6 patients
[38%]), consent withdrawal (OCA 10 mg, 1 patient
[5%]), and major protocol violation (OCA 50 mg, 1
patient [6%]). One patient (6%) in the OCA 50 mg
group had been receiving 200 mg fenoﬁbrate orally for
fatigue while in the study but discontinued due to
pruritus.

PRIMARY ENDPOINT
Both doses of OCA were superior to placebo in
achieving the primary endpoint at EOS (Fig. 1A).
ALP was signiﬁcantly reduced in the OCA 10 mg and
OCA 50 mg groups by 53.9% (262.5, 229.3) and
37.2% (254.8, 224.6), respectively, compared to 0.8%
(26.4, 8.7) in the placebo group (P < 0.0001).

SECONDARY ENDPOINTS
ALP (units per liter) was signiﬁcantly reduced from
baseline in both OCA groups compared to placebo
(P  0.0001) throughout double-blind treatment
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TABLE 1. Demographic and Baseline Characteristics of PBC Patients
Placebo
(n 5 23)
Female, n (%)
White, n (%)
Age (years)
Body weight (kg)
Body mass index (kg/m2)
Estimated 10-year survival (Global-PBC)*
Estimated 10-year survival (UK-PBC)†
PBC duration (years)‡
Albumin (g/L)
Platelets (109/L)
Total cholesterol (mg/dL)
IgM (g/L)
ALP (U/L)
GGT (U/L)
AST (U/L)
ALT (U/L)
Conjugated bilirubin (mg/dL)
Total bilirubin (mg/dL)

20
21
54
78.1
28.9
90.5
98.6
1.0
40.0
314
226.5
3.0
321
359
64
63
0.18
0.55

OCA 10 mg
(n 5 20)

(87)
(91)
(48, 63)
(63.0, 99.9)
(23.3, 33.3)
(85.2, 93.7)
(97.4, 99.0)
(0.2, 6.3)
(37.0, 42.0)
(213, 386)
(178.6, 259.1)
(2.7, 4.3)
(234, 586)
(242, 625)
(42, 99)
(50, 97)
(0.11, 0.30)
(0.38, 0.80)

14
19
54
77.7
25.3
82.6
97.6
1.1
38.9
260
229.3
2.7
366
550
54
71
0.22
0.65

(70)
(95)
(47, 62)
(67.1, 82.5)
(24.7, 29.0)
(74.5, 92.9)
(92.6, 98.3)
(0.2, 7.4)
(34.5, 43.2)
(226, 313)
(201.1, 282.8)
(1.9, 3.6)
(236, 623)
(412, 962)
(41, 91)
(57, 124)
(0.17, 0.40)
(0.49, 0.95)

OCA 50 mg
(n 5 16)
16
16
54
59.5
22.7
91.0
98.4
2.1
40.5
269
222.0
3.8
379
344
58
64
0.20
0.51

(100)
(100)
(49, 61)
(54.0, 73.5)
(20.8, 28.0)
(85.7, 94.6)
(96.5, 98.8)
(0.2, 9.3)
(38.1, 43.5)
(217, 329)
(210.4, 242.5)
(2.7, 6.3)
(306, 590)
(258, 449)
(52,64)
(45, 79)
(0.18, 0.26)
(0.39, 0.82)

Data are median (Q1, Q3) unless otherwise speciﬁed. Normal ranges: albumin, 31-52 g/L; platelets, 121-450 109/L; total cholesterol,
69.5-231.7 mg/dL; IgM, 0.4-2.3 g/L; ALP, 117 U/L (female), 129 U/L (male); GGT, 50 U/L (female), 73 U/L (male);
AST, 50 U/L; ALT, 67 U/L; conjugated bilirubin: 0.41 mg/dL; total bilirubin: 1.40 mg/dL.
*Baseline 10-year survival estimated by the Global-PBC score.
†
Baseline 10-year survival estimated by the UK-PBC score.
‡
PBC duration is based on the day of diagnosis from individual medical histories.

(Fig. 1B; Supporting Fig. S2A). At month 3/ET, the
change from baseline in ALP in the OCA 10 mg and
OCA 50 mg groups was 2159 (2379, 2112) and
2148 (2217, 274), respectively, compared with 1
(218, 49) in the placebo group (P < 0.0001). At the

follow-up visit (2 weeks after terminating treatment),
ALP levels trended toward baseline values; however,
they remained reduced in the OCA 10 mg (P < 0.0001)
and OCA 50 mg (P 5 0.0092) groups compared to
placebo.



FIG. 1. OCA reduces ALP. (A) Percent change in ALP at EOS. (B) ALP change from baseline. Data are median (Q1, Q3). **P <
0.01, ***P < 0.0001; P values determined by pairwise comparisons using a two-sided Wilcoxon-Mann-Whitney test comparing
changes in each OCA group with the placebo group. Note: the primary endpoint includes ET values or last observation carried forward values. ALP change from baseline values at month 3 include the ET visit data for patients who discontinued where available.
Abbreviation: BL, baseline.
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FIG. 2. Effect of OCA on liver biochemistries. (A) GGT change from baseline. (B) AST change from baseline. (C) ALT change
from baseline. (D) Conjugated bilirubin change from baseline. Data are median (Q1, Q3). Change from baseline values at month 3
include the ET visit data for patients who discontinued. *P < 0.05, **P < 0.01, ***P < 0.0001; P values determined by pairwise comparisons using a two-sided Wilcoxon-Mann-Whitney test comparing changes in each OCA group with the placebo group. Abbreviation: BL, baseline.


With OCA treatment, GGT (units per liter)
decreased signiﬁcantly from baseline (P < 0.0001)
throughout the double-blind phase (Fig. 2A; Supporting Fig. S2B). AST (units per liter) levels in the OCA
10 mg group and the OCA 50 mg group also
decreased from baseline to month 3/ET (Fig. 2B; Supporting Fig. S2C). Changes in AST at month 3/ET
were not different between treatment groups; however,
baseline values were only modestly elevated from normal (Table 1), and levels in the OCA 10 mg group
approached normal range (AST 50 U/L) by week 2
and fell within normal range for the remainder of the
study. Signiﬁcant reductions in ALT (units per liter)

from baseline to month 3/ET were observed in both
OCA groups compared to placebo (OCA 10 mg, P 5
0.0150; OCA 50 mg, P 5 0.0476) (Fig. 2C; Supporting Fig. S2D). Conjugated bilirubin (milligrams per
deciliter) was decreased from baseline in both OCA 10
mg (P 5 0.0177) and OCA 50 mg (P 5 0.0266)
groups compared to an increase at month 3/ET in the
placebo group (Fig. 2D; Supporting Fig. S2E). At the
follow-up visit, GGT, AST, ALT, and conjugated bilirubin levels trended toward baseline values following
withdrawal of OCA.
Various biochemical disease severity criteria have
been derived, and achieving these criteria was
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TABLE 2. Exploratory Biomarkers
Placebo
Baseline

Change From
Baseline

Inflammatory and immunomodulatory biomarkers
hsCRP (mg/L)
11.2
0.0
(5.6, 16.1)
(25.7, 2.1)
n 5 21
n 5 19

OCA 10 mg

OCA 50 mg

P

Baseline

Change From
Baseline

23.0
(25.3, 21.5)
n 5 15

0.1105

5.0
(3.6, 9.6)
n 5 13

21.4
(24.5, 0.3)
n 5 11

0.3016

Baseline

Change From
Baseline

5.6
(4.0, 7.8)
n 5 17

P

TNF-a (ng/L)

15.1
(12.6,17.4)
n 5 18

0.4
(21.0, 3.6)
n 5 15

14.9
(12.0, 19.4)
n 5 14

21.1
(23.3, 0.0)
n 5 13

0.1119

16.1
(11.7, 21.0)
n 5 12

22.2
(23.7, 20.6)
n59

0.0061

TGF2b
(lg/L)

19.0
(16.2, 28.4)
n 5 10

1.0
(0.3, 1.4)
n 5 10

24.0
(19.2, 26.8)
n58

24.1
(26.5, 7.0)
n57

0.7327

21.5
(19.3, 28.1)
n56

1.9
(0.1, 4.7)
n56

0.7042

IgM (g/L)

3.0
(2.7, 4.3)
n 5 17

0.0
(20.3, 0.2)
n 5 13

2.7
(1.9, 3.6)
n 5 14

20.6
(20.9, 20.1)
n 5 11

0.0205

3.8
(2.7, 6.3)
n 5 11

21.0
(21.9, 20.6)
n59

0.0033

Osteopontin
(lg/L)

229
(169, 324)
n58

60
(219, 91)
n57

320
(166, 357)
n57

15
(263, 125)
n57

0.8983

217
(180, 264)
n57

181
(134, 252)
n55

0.0348

Glutathione
(lmol/L)

2.3
(2.0, 4.7)
n59

0.2
(20.5, 0.7)
n57

2.3
(1.2, 3.1)
n57

1.9
(0.4, 3.0)
n57

0.0151

4.2
(1.3, 5.9)
n57

0.2
(0.1, 2.1)
n55

0.6261

Noninvasive measures of liver fibrosis
ELF score
9.2
20.1
(8.6, 9.8)
(20.2, 0.4)
n 5 22
n 5 21

9.3
(8.2, 9.7)
n 5 20

0.2
(20.1, 0.5)
n 5 19

0.2334

9.2
(8.9, 9.3)
n 5 14

0.0
(20.4, 0.3)
n 5 14

0.6738

HA (ng/mL)

49.6
(24.2, 78.0)
n 5 22

0.2
(211.5, 12.9)
n 5 21

45.8
(24.9, 71.9)
n 5 20

10.2
(23.2, 30.4)
n 5 19

0.1436

40.8
(27.5, 77.2)
n 5 14

1.8
(212.6, 10.5)
n 5 14

0.8796

P3NP
(ng/mL)

6.5
(5.8, 11.4)
n 5 22

0.3
(20.8, 1.3)
n 5 21

7.5
(5.0, 9.0)
n 5 20

20.2
(21.2, 2.76)
n 5 19

0.6648

8.2
(4.8, 10.7)
n 5 14

20.4
(21.2, 1.3)
n 5 14

0.8531

TIMP-1
(ng/mL)

767
(601, 906)
n 5 22

233
(2133, 73)
n 5 21

799
(661, 897)
n 5 20

280
(2197, 234)
n 5 19

0.2229

785
(689, 854)
n 5 14

269
(2121, 221)
n 5 14

0.7491

21.3
(3.0, 0.0)
n 5 22

38.9
(34.5, 43.2)
n 5 20

20.6
(22.1, 1.5)
n 5 19

0.4404

40.5
(38.1, 43.5)
n 5 16

21.0
(22.8, 1.5)
n 5 15

0.6205

Additional measures of liver function
Albumin (g/L)
40.0
(37.0, 42.0)
n 5 23
Platelets
(109/L)

314
(213, 386)
n 5 23

26
(234, 21)
n 5 23

260
(226, 313)
n 5 20

26
(234, 22)
n 5 19

0.9798

269
(217, 329)
n 5 16

2
(210, 35)
n 5 14

0.4154

Serum bile
acids
(lmol/L)

8.1
(6.9, 12.9)
n59

0.9
(21.1, 7.5)
n56

9.4
(7.2, 11.4)
n57

21.5
(22.6, 3.6)
n57

0.5203

6.0
(5.8, 23.9)
n57

20.5
(28.6, 0.4)
n54

0.5940

INR

1.00
(0.98, 1.07)
n 5 23

20.02
(20.05, 0.07)
n 5 23

1.01
(0.98, 1.05)
n 5 20

20.04
(20.07, 0.01)
n 5 19

0.1606

0.99
(0.96, 1.05)
n 5 16

0.00
(20.11, 0.07)
n 5 15

0.6977

0.5
(0.3, 0.6)
n59

20.1
(20.3, 0.1)
n56

0.5
(0.3, 0.9)
n57

0.1
(20.7, 0.3)
n57

0.7206

0.4
(0.1, 0.6)
n57

0.1
(20.1, 0.5)
n54

0.3359

NEFA
(mmol/L)

Data are median (Q1, Q3); P values are for median change from baseline to month 3 based on a Wilcoxon-Mann-Whitney comparison. Change from baseline values at month 3 include the ET visit data for patients who discontinued. Normal ranges: hsCRP, 3.0
mg/L; TNF-a, 8.1 ng/L; TGF-b, 21.0-82.0 lg/L; IgM, 0.4-2.3 g/L; osteopontin, 171-667 lg/L; glutathione, 2.4-4.4 lmol/L;
albumin, 31.0-52.0 g/L; platelets, 121-450 109/L; bile acids, 10 lmol/L; INR, 0.76-1.27; NEFA, 0.1-0.45 mmol/L (female), 0.10.60 mmol/L (male).
Abbreviations: ELF, enhanced liver ﬁbrosis; HA, hemagglutinin; INR, international normalized ratio; NEFA, nonesteriﬁed fatty acids;
P3NP, procollagen type 3 N-terminal peptide; TGF-b, transforming growth factor-b; TIMP-1, tissue inhibitor of metalloproteinase 1.
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FIG. 3. Markers of FXR activation. (A) FGF-19 change from baseline to month 3/ET. Baseline FGF-19 was 77.5 (27.6, 85.5),
109.7 (86.3, 228.3), and 74.7 (48.8, 144.3) for placebo, OCA 10 mg, and OCA 50 mg groups, respectively. (B) C4 change from
baseline to month 3/ET. Baseline C4 was 18.2 (8.9, 22.3), 8.6 (4.3, 19.0), and 9.1 (6.5, 27.4) for placebo, OCA 10 mg and OCA 50
mg groups, respectively. Data are median (Q1, Q3). Change from baseline values at month 3 include the ET visit data for patients
who discontinued. *P < 0.05; P values determined by pairwise comparisons using a two-sided Wilcoxon-Mann-Whitney test comparing changes in each OCA group with the placebo group.


prognostic of improved outcomes in PBC.(5) A signiﬁcantly greater percentage of OCA-treated patients met
these biochemical disease severity criteria compared to
placebo at month 3/ET with the exception of 1 (ALP
3 times ULN, AST 2 times ULN, and total bilirubin 1 mg/dL, Paris I criterion) (Supporting Table
S2). The Barcelona criterion (ALP >40% decrease or
normal ALP) was the most discriminating; no patients
in the placebo group met this criterion at month 3/ET
compared with 70% in OCA 10 mg (P < 0.0001) and
44% in OCA 50 mg (P 5 0.0006) groups.

EXPLORATORY ENDPOINTS
The ALP levels in both OCA groups decreased substantially by month 3/ET, with 50% of patients in
each of the OCA groups (P < 0.01) achieving ALP
<1.67 times ULN (Supporting Fig. S3). In the OCA
10 mg group 25% of patients (P 5 0.0155) achieved
normal ALP, although no patients in the OCA 50 mg
or placebo group achieved normal ALP.
Dose-dependent increases in FGF-19 (nanograms
per liter) were observed, conﬁrming FXR activation.
The change from baseline to month 3/ET was 176.5
(39.0, 8898.7) in the OCA 50 mg group (P 5 0.0154)
but not signiﬁcant in the OCA 10 mg group (106.4
[20.8, 132.2], P 5 0.2857) compared to placebo (10.7

[210.3, 81.7]) (Fig. 3A). Baseline IgM levels (grams
per liter) were above ULN in all treatment groups and
signiﬁcantly reduced at month 3/ET in both OCA
treatment groups (OCA 10 mg, 20.6 [20.9, 20.1], P
5 0.0205; OCA 50 mg, 21.0 [21.9, 20.6], P 5
0.0033) versus placebo (0.0 [20.3, 0.2]) (Table 2).
Changes from baseline to month 3/ET in TNF-a and
osteopontin were signiﬁcant only in the OCA 50 mg
group, with a decrease in TNF-a (P 5 0.0061) and an
increase in osteopontin (P 5 0.0348). Glutathione
increased from baseline to month 3/ET in the OCA
10 mg group (P 5 0.0151) compared to placebo, with
no signiﬁcant change observed in the OCA 50 mg
group. There were no differences between treatment
groups from baseline to month 3/ET in change in
hsCRP, transforming growth factor-b, or enhanced
liver ﬁbrosis score (and all enhanced liver ﬁbrosis components) (Table 2). There were no changes from baseline to month 3/ET in albumin, platelets, international
normalized ratio, or nonesteriﬁed fatty acids with
OCA treatment; all remained in the normal range.
Baseline serum bile acid levels (micromoles per liter)
were in the normal range; however, OCA treatment
resulted in reductions from baseline (OCA 10 mg,
21.5 [22.6, 3.6], P 5 0.5203; OCA 50 mg, 20.5
[28.6, 0.4], P 5 0.5940) but not signiﬁcantly compared to placebo (0.9 [21.1, 7.5]).
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TABLE 3. Incidence of Treatment-Emergent AEs Occurring
in >10% Patients in Any OCA Group*
Treatment Group
Placebo
(n 5 23)
Patients (%)
Patients with any AEs
Pruritus
Abdominal distension
Abdominal pain
Constipation
Diarrhea
Feces pale
Hemorrhoids
Nausea
Nasopharyngitis
Urinary tract infection
Headache
Insomnia

21 (91)
8 (35)
0 (0)
1 (4)
0 (0)
1 (4)
0 (0)
0 (0)
4 (17)
2 (9)
0 (0)
5 (22)
1 (4)

OCA 10 mg
(n 5 20)
Patients (%)
18
14
0
1
0
0
0
0
0
3
3
4
1

(90)
(70)
(0)
(5)
(0)
(0)
(0)
(0)
(0)
(15)
(15)
(20)
(5)

OCA 50 mg
(n 5 16)
Patients (%)
15
15
2
2
2
2
2
2
4
1
1
2
2

(94)
(94)
(13)
(13)
(13)
(13)
(13)
(13)
(25)
(6)
(6)
(13)
(13)

*Any patient who received at least one dose of any treatment.

Assessment of quality of life using the Short Form 36
survey showed no changes between treatment groups
from baseline to month 3/ET in any of the Short Form
36 domains (Supporting Table S3). With the exception
of increased itch (OCA 50 mg, P 5 0.0172) and
reduced fatigue (OCA 10 mg, P 5 0.0451), no signiﬁcant changes were observed in any of the remaining
PBC-40 domains (Supporting Table S3).

POST HOC ASSESSMENTS
FXR activation was further assessed post hoc by analyzing the concentration of C4 (nanograms per milliliter). No change was observed between baseline and
month 3/ET in placebo (0.2 [–3.6, 0.8]), but there
was a decrease of 26.5 (215.8, 23.9) observed in the
OCA 50 mg group (P 5 0.0485; Fig. 3B). A similar
reduction was observed in the OCA 10 mg group
(26.8 [215.5, 21.7]), but this was not signiﬁcant
(P 5 0.0508).
The Global-PBC and UK-PBC prognostic models
were used to estimate long-term survival before and
after OCA treatment.(16,17) Supporting Fig. S4A,B
shows the estimated survival at 5, 10, and 15 years in
all treatment groups prior to receiving treatment. The
baseline survival estimated by both prognostic models
at 5, 10, and 15 years appears worse for the OCA 10
mg group compared to the placebo and OCA 50 mg
groups. This may be due to lower platelets and elevated
total bilirubin and ALT in the OCA 10 mg group at
baseline, which are components of the models. After 3
months of treatment, both models predict worsening
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survival in patients receiving placebo and improved
survival in both OCA groups (P < 0.01) (Supporting
Fig. S4C,D).

SAFETY ASSESSMENTS
While the incidence of AEs was similar across all
treatment groups, pruritus was the most common AE
in all treatment groups, particularly in the OCA
groups (placebo, 35%; OCA 10 mg, 70%; and OCA
50 mg, 94%) (Table 3). The incidence and severity of
pruritus were dose-dependent with OCA; 15% of
patients in the OCA 10 mg and 38% of patients in the
OCA 50 mg discontinued due to pruritus (Supporting
Fig. S1 and Table S1). At month 3/ET, there was a
signiﬁcant increase from baseline in the pruritus visual
analogue scale score in both OCA groups compared to
placebo (P < 0.05) (Supporting Fig. S5A). No differences between treatment groups were observed at
month 3/ET in the total score of the 5D pruritus questionnaire (Supporting Fig. S5B). The median time to
onset of pruritus was 33, 14, and 6 days in the placebo,
OCA 10 mg, and OCA 50 mg groups, respectively. In
the placebo, OCA 10 mg, and OCA 50 mg groups 6/
6, 7/7, and 3/4 patients, respectively, experienced AEs
of pruritus but received no intervention and completed
the double-blind phase of the study. Interventions for
pruritus were successful in 3/3, 6/9, and 7/13 patients
in the placebo, OCA 10 mg, and OCA 50 mg groups,
respectively (Supporting Table S4). Medications were
the most frequent intervention used for pruritus, speciﬁcally the bile acid sequestrant cholestyramine (Supporting Table S4). Dose frequency adjustments were
typically a reduction to dosing on alternate days.
Other than pruritus, there were no trends in either
OCA group with respect to AEs leading to study discontinuation. A single serious AE (rash) was reported
in the double-blind phase by a placebo-treated patient.
Results of QT interval corrected by the Fridericia formula were comparable across all treatment groups at
baseline and did not change after treatment (Supporting Table S5). Baseline cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol, and triglyceride levels were comparable
across treatment groups (Supporting Table S6). At
month 3/ET, OCA treatment resulted in decreases
from baseline in total cholesterol (milligrams per deciliter) (placebo, 22.5 [–16.0, 8.7]; OCA 10 mg, 22.9
[255.6, 7.1]; OCA 50 mg, –16.2 [249.0, 4.6]) and
HDL-C (milligrams per deciliter) (placebo, 23.1
[28.5, 2.9]; OCA 10 mg, 28.5 [227.2, 0.4]; OCA
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50 mg, –13.5 [226.8, 22.5]) and increases in lowdensity lipoprotein cholesterol (milligrams per deciliter) (placebo, 23.7 [29.1, 5.6]; OCA 10 mg, 11.6
[24.8, 14.5]; OCA 50 mg, 6.8 [23.5, 29.3]). There
were no dose-dependent changes in triglycerides at
month 3/ET (placebo, 24.4 [214.2, 17.3]; OCA 10
mg, 23.1 [–20.4, 26.6]; OCA 50 mg, 20.4 [–45.1,
9.3]).

OPEN-LABEL EXTENSION
Twenty-eight (47%) patients enrolled in the OLE
phase (18 patients completed through 6 years). The
median (Q1, Q3) treatment duration was 6.4 (2.5, 6.7)
years, and the median weighted average daily dose was
14.0 mg (10.0, 22.5). After the end of double-blind
treatment, 12 patients (43%) initiated UDCA based
on the investigator’s discretion. Changes in ALP,
GGT, AST, ALT, and conjugated bilirubin were sustained for up to 6 years in patients who continued
OCA treatment (Fig. 4). Pruritus was the most common AE reported during the OLE, experienced by
89% of patients (Supporting Table S7). Twenty
patients (71%) received concomitant medications for
pruritus including antihistamines, bile acid sequestrants, and antibiotics (typically rifampicin). A total of
12 patients (43%) discontinued due to several causes:
pruritus (3 patients, 11%), other AEs (4 patients, 14%:
cirrhosis, arthralgia, colitis, lab abnormality), consent
withdrawal (1 patient, 4%), or other reasons (4
patients, 14%). The safety proﬁle in the OLE was consistent with the double-blind phase.

Discussion
It is important to understand the safety and efﬁcacy
of OCA as a potential monotherapy, which has a distinct mechanism of action from UDCA. This doubleblind, placebo-controlled study evaluated the efﬁcacy
and safety of OCA monotherapy in patients with
PBC. The primary endpoint, percent change in ALP,
was achieved with signiﬁcant reductions following
OCA treatment. OCA treatment improved markers of
cholestasis, hepatocellular damage, and liver function,
which were similarly observed in OCA-treated
patients through 6 years of open-label treatment, suggesting a durable response without additional safety
ﬁndings. OCA also increased circulating FGF-19 and
decreased C4 levels, demonstrating FXR activation.
The efﬁcacy of OCA 10 mg was comparable to OCA
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50 mg, but OCA 10 mg was associated with improved
tolerability and fewer discontinuations.
Evaluation of new compounds administered as
monotherapy is the optimal way to deﬁne the properties of a drug in a disease regardless of whether subsequent use is in combination with other agents.
Previous studies of OCA in combination with UDCA
in patients with PBC have shown signiﬁcant biochemical improvements.(8,15) However, this study conﬁrms
that the biochemical improvements observed with
OCA occur in the absence of UDCA, further underlining the role of FXR in the regulation of bile acids
and cholestatic disease.
In this study, baseline ALP was markedly elevated
to 3.2 times ULN in the absence of UDCA. In a
parallel study evaluating OCA in combination with
UDCA, baseline ALP was elevated to 2.3 times
ULN.(8) Both studies used the same entry criterion for
ALP, assessed OCA 10 mg and 50 mg doses, and
were of identical duration. In both studies, at the end
of the 3-month double-blind phase, ALP was 1.7
times ULN in OCA-treated patients, suggesting that
OCA can achieve clinically meaningful reductions in
ALP in patients who either are intolerant/naive to
UDCA or have an inadequate response to UDCA.
Interestingly, ALP reductions observed in this OCA
monotherapy study are similar to reductions reported
in previous studies of UDCA (40%-60%).(19)
UDCA has been associated with improvements in
markers of cholestasis as well as various markers of
hepatic damage.(20-23) Importantly, the mechanism by
which UDCA elicits these effects is independent of
FXR activation as UDCA has no afﬁnity for FXR.(24)
In contrast, OCA is a selective FXR agonist, eliciting
its effects through transcriptional regulation of bile acid
homeostasis demonstrated by increases in FGF-19 with
concomitant reductions of bile acid synthesis.(11-13) In
this study, FGF-19 increased dose-dependently, but the
reduction in C4 was similar between both OCA doses,
suggesting that the effect on cholesterol 7a-hydroxylase
was saturated, resulting in nearly equal C4 reductions.
In this study, reductions in serum bile acids were not
signiﬁcant with OCA treatment due to normal baseline
levels and low patient numbers; in larger studies, OCA
has been associated with reductions in serum bile
acids.(8,15) Mechanistically, OCA-driven inhibition of
endogenous bile acid synthesis and choleretic properties
can be effective as monotherapy and can complement
UDCA therapy.(8,10)
In addition to FXR-mediated effects on bile acid
homeostasis, OCA treatment has been associated with
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FIG. 4. Changes in liver biochemistry over 6 years of OLE. (A) ALP change from baseline. (B) GGT change from baseline. (C)
AST change from baseline. (D) ALT change from baseline. (E) Conjugated bilirubin change from baseline. For all plots, values presented are median (Q1, Q3) of all patients participating in the trial at any point regardless of dose or group. Dashed line represents
the median change from baseline at the end of the double-blind phase. Off-Rx refers to the study period from month 3 and initiating
OCA during the OLE. Abbreviation: BL, baseline.


immunomodulatory and anti-inﬂammatory effects.(15)
PBC is characterized by loss of tolerance to mitochondrial self-antigens and frequent autoimmune comorbidities. Genome-wide studies have shown signiﬁcant
associations between PBC and a range of genetic
markers.(25,26) Furthermore, presence of antimitochondrial antibodies is diagnostic for PBC, and elevated IgM

1900

levels are commonly observed in patients with
PBC.(3,4,27) OCA monotherapy improved markers of
immunity and inﬂammation including IgM and
TNF-a. In this study transforming growth factor-b
and hsCRP were not different between the placebo
and OCA groups; however, in larger studies, OCA
has been associated with improvements in hsCRP.(8,15)
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PBC is a chronic liver disease, making early prediction of long-term prognosis critical for risk stratiﬁcation and disease management. ALP(28) and
bilirubin,(7) along with aminotransferases, have been
used in previous response criteria and have served as
endpoints for clinical trials.(6) OCA monotherapy
resulted in a greater percentage of patients achieving
most published treatment response criteria compared
to placebo. Furthermore, OCA monotherapy signiﬁcantly increased predicted survival compared to placebo
as assessed by the UK-PBC and Global-PBC prognostic models, which have shown improved accuracy
in predicting clinical outcomes in PBC versus dichotomous response criteria.(16,17) Both prognostic models
were evaluated post hoc as they were developed after
this study was initiated. The improved predicted survival using both prognostic models reﬂects improvements in ALP together with other variables within the
models. The utility of survival predictions in this study
was limited by the short OCA treatment period and
small patient population. Furthermore, these prognostic models were developed to predict clinical outcomes
following 1 year of UDCA treatment and have not yet
been validated for use with OCA. A phase 3 study
evaluating clinical outcomes with OCA in patients
with PBC (COBALT; ClinicalTrials.gov identiﬁer
NCT02308111; EudraCT no. 2014-005012-42) is
ongoing and may be used to test the utility of these
prognostic models with OCA. Nevertheless, the results
are promising given that 3 months of OCA monotherapy resulted in measurable and signiﬁcant improvements in predicted survival.
Pruritus, a common symptom of PBC,(29) was experienced by 35%, 70%, and 94% of patients receiving
placebo, OCA 10 mg, and OCA 50 mg, respectively.
The incidence of pruritus in the placebo and OCA 10
mg groups in this study was consistent with the incidence observed in a phase 3 study of OCA in combination with UDCA.(15) Pruritus was manageable by
antipruritic agents or temporary OCA interruption.
Most patients who received a clinical intervention to
manage pruritus completed the study regardless of
OCA dose. OCA 50 mg was determined to be excessive as it resulted in 38% of patients discontinuing
treatment due to pruritus without providing additional
clinical beneﬁt, as assessed by the comparable changes
in ALP and other markers relative to OCA 10 mg
(although the higher discontinuation rate in the OCA
50 mg group, which typically occurred shortly after initiating OCA, likely reduced observed efﬁcacy as ET
results were included with month 3 data). The phase 3
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study of OCA in patients with PBC (including 7%
who were receiving OCA monotherapy) investigating
OCA 10 mg versus OCA 5 mg titrating to OCA 10
mg based on response and tolerability conﬁrmed the
beneﬁt of dose titration in managing pruritus.(15)
Hypercholesterolemia and altered lipoprotein proﬁles are commonly seen in PBC, occurring in 75%95% of patients.(30,31) Similar to other clinical studies
of OCA in patients with PBC,(8,15) OCA monotherapy resulted in a reduction in total cholesterol driven
by decreased HDL-C. The mechanism underlying the
OCA-driven reduction in HDL-C remains to be conﬁrmed; it is hypothesized that the reduction is due to
FXR-mediated up-regulation of the surface HDL
scavenger receptor B1, which would increase hepatic
uptake of cholesterol from HDL.(32)
This study had several limitations, including a small
patient population due to the near-ubiquitous use of
UDCA and a short double-blind phase. The brevity of
the double-blind phase, however, is complemented by
the ongoing OLE. The study did not incorporate the
OLE phase into the original study design as the period
between the double-blind phase and the OLE was variable between patients. This potentially impeded
recruitment of patients into the OLE, and several
patients initiated UDCA between the two phases.
While the OLE has been ongoing for over 6 years, the
small patient population and addition of UDCA in
some patients limit interpretation of data from the
OLE. An additional limitation of this study is that the
reason patients were not receiving UDCA at baseline
was not captured.
In summary, OCA may provide an effective therapeutic option for patients with PBC in the absence of
UDCA. The advent of effective second-line therapy
for PBC in the form of OCA is transforming the landscape, and it is important that we understand how to
best use existing and emerging therapies. It is unclear
if OCA may prove to have a role as a ﬁrst-line therapy
in PBC, but the results of this study demonstrate that
OCA is efﬁcacious when given as monotherapy with a
durable response with continuing treatment. This is
particularly encouraging for the small but important
group of PBC patients who cannot tolerate UDCA.
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